Press Releases Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 08/12/2025 pm IST			5-day change	1st Jan Change
2,056.00 ^DKK	+1.18%		+0.83%	+37.76%

09/12	Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms	MT
08/12	Genmab announces data from multiple clinical trials	RE

Press Releases

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)	09/12	BU
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)	09/12	GL
Genmab Presents Pivotal Phase 3 Data from EPCORE(R) FL-1 Trial Demonstrating Clinical Benefit of EPKINLY(R) (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2)	08/12	AQ
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)	08/12	AQ
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma	07/12	GL
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma	07/12	BU
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)	06/12	BU
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)	06/12	GL
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	04/12	GL
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	02/12	GL
Genmab A/S : Articles of association dated November 20, 2025 – English	26/11	PU
Genmab A/S : has published its Articles of Association	26/11	PU
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami	24/11	GL
Grant of Restricted Stock Units and Warrants to Employees in Genmab	21/11	GL
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	19/11	GL
Genmab A/S : Articles of association dated November 18, 2025 – English	19/11	PU
Genmab A/S : has published its Articles of Association	19/11	PU
Genmab Announces EPKINLY in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	19/11	AQ
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility	19/11	GL
Capital Increase in Genmab as a Result of Employee Warrant Exercise	19/11	GL
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	18/11	BU
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	18/11	GL
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes	10/11	GL
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility	10/11	GL
Genmab A/S : First Nine Months 2025 Financial Results Presentation	06/11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Genmab advances on earnings strength and pipeline while lower valuation opens upside

November 07, 2025 at 08:31 pm IST

Genmab: From now on, courage to the most patient

April 01, 2025 at 08:27 pm IST